JP6426693B2 - 抗ｃｄ４７薬の処理上有効量を達成するための方法 - Google Patents

抗ｃｄ４７薬の処理上有効量を達成するための方法 Download PDF

Info

Publication number
JP6426693B2
JP6426693B2 JP2016500441A JP2016500441A JP6426693B2 JP 6426693 B2 JP6426693 B2 JP 6426693B2 JP 2016500441 A JP2016500441 A JP 2016500441A JP 2016500441 A JP2016500441 A JP 2016500441A JP 6426693 B2 JP6426693 B2 JP 6426693B2
Authority
JP
Japan
Prior art keywords
dose
hu5f9
drug
sirpα
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016500441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513640A5 (Direct
JP2016513640A (ja
Inventor
ウィリンガム，スティーブン
ハワード，モーリーン
リュウ，ジィー
マジェティ，ラビンドラ
スウィーニー プロハスカ，スーザン
スウィーニー プロハスカ，スーザン
ケイ． ボルクマー，アン
ケイ． ボルクマー，アン
ボルクマー，イェンス−ペーター
エル． ワイスマン，アービング
エル． ワイスマン，アービング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51580621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6426693(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2016513640A publication Critical patent/JP2016513640A/ja
Publication of JP2016513640A5 publication Critical patent/JP2016513640A5/ja
Application granted granted Critical
Publication of JP6426693B2 publication Critical patent/JP6426693B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016500441A 2013-03-15 2014-02-26 抗ｃｄ４７薬の処理上有効量を達成するための方法 Active JP6426693B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361800102P 2013-03-15 2013-03-15
US61/800,102 2013-03-15
PCT/US2014/018743 WO2014149477A1 (en) 2013-03-15 2014-02-26 Methods for achieving therapeutically effective doses of anti-cd47 agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018201216A Division JP6704974B2 (ja) 2013-03-15 2018-10-25 抗ｃｄ４７薬の処理上有効量を達成するための方法

Publications (3)

Publication Number Publication Date
JP2016513640A JP2016513640A (ja) 2016-05-16
JP2016513640A5 JP2016513640A5 (Direct) 2017-03-30
JP6426693B2 true JP6426693B2 (ja) 2018-11-21

Family

ID=51580621

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016500441A Active JP6426693B2 (ja) 2013-03-15 2014-02-26 抗ｃｄ４７薬の処理上有効量を達成するための方法
JP2018201216A Active JP6704974B2 (ja) 2013-03-15 2018-10-25 抗ｃｄ４７薬の処理上有効量を達成するための方法
JP2020084674A Active JP7007422B2 (ja) 2013-03-15 2020-05-13 抗ｃｄ４７薬の処理上有効量を達成するための方法
JP2022001223A Active JP7246528B2 (ja) 2013-03-15 2022-01-06 抗ｃｄ４７薬の処理上有効量を達成するための方法
JP2023039709A Active JP7562736B2 (ja) 2013-03-15 2023-03-14 抗ｃｄ４７薬の処理上有効量を達成するための方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018201216A Active JP6704974B2 (ja) 2013-03-15 2018-10-25 抗ｃｄ４７薬の処理上有効量を達成するための方法
JP2020084674A Active JP7007422B2 (ja) 2013-03-15 2020-05-13 抗ｃｄ４７薬の処理上有効量を達成するための方法
JP2022001223A Active JP7246528B2 (ja) 2013-03-15 2022-01-06 抗ｃｄ４７薬の処理上有効量を達成するための方法
JP2023039709A Active JP7562736B2 (ja) 2013-03-15 2023-03-14 抗ｃｄ４７薬の処理上有効量を達成するための方法

Country Status (11)

Country Link
US (8) US9623079B2 (Direct)
EP (3) EP2970493B1 (Direct)
JP (5) JP6426693B2 (Direct)
CN (3) CN112245586A (Direct)
AU (4) AU2014238105B2 (Direct)
CA (1) CA2903773A1 (Direct)
DK (1) DK2970493T3 (Direct)
ES (1) ES2728066T3 (Direct)
IL (1) IL241347B (Direct)
PT (1) PT2970493T (Direct)
WO (1) WO2014149477A1 (Direct)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072655B2 (en) * 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
CA2965198C (en) 2008-01-15 2021-02-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
SG11201504469XA (en) 2012-12-12 2015-07-30 Vasculox Inc Therapeutic cd47 antibodies
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
EP2970493B1 (en) 2013-03-15 2019-04-03 The Board of Trustees of the Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents
WO2015041987A1 (en) 2013-09-18 2015-03-26 The Board Of Trustees Of The Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
US10550187B2 (en) * 2014-10-24 2020-02-04 Incept, Llc Extra luminal scaffold
RU2576614C1 (ru) * 2015-01-19 2016-03-10 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "33 ЦЕНТРАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИСПЫТАТЕЛЬНЫЙ ИНСТИТУТ" Минобороны России Способ поиска точки с дробным эффектом при определении эффективных доз веществ методом "одной точки"
WO2016118754A1 (en) * 2015-01-21 2016-07-28 The Board Of Trustees Of The Leland Stanford Junior University Macrophages eat cancer cells using their own calreticulin as a guide
WO2016138306A1 (en) 2015-02-27 2016-09-01 The Board Of Trustees Of The Leland Stanford Junior University Combination therapy for treatment of coronary artery disease
EP3331902B1 (en) 2015-08-07 2021-04-28 ALX Oncology Inc. Constructs having a sirp-alpha domain or variant thereof
CA3002789A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
WO2017049251A2 (en) 2015-09-18 2017-03-23 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
HK1257309A1 (zh) 2015-09-21 2019-10-18 Erasmus University Medical Center 抗-cd47抗体及使用方法
AU2016365829B2 (en) * 2015-12-11 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with dual targeting of CD47 and EGFR
AU2017210224B2 (en) * 2016-01-21 2024-02-08 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents
CA3019676A1 (en) * 2016-04-15 2017-10-19 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
US9957576B2 (en) 2016-04-21 2018-05-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
CA3019841A1 (en) 2016-04-29 2017-11-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the prevention and treatment of surgical adhesions
WO2018014067A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Anti-cd47 combination therapy
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
WO2018081448A1 (en) * 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
CA3042583A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
CA3053392A1 (en) 2017-02-28 2018-09-07 The Board Of Trustees Of The Leland Stanford Junior University Antifibrotic activity of cd47 blockade
WO2018165015A1 (en) 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
PT3642242T (pt) 2017-06-21 2024-04-16 Univ Leland Stanford Junior Parâmetros de dosagem para terapias de direcionamento de cd47 para malignidades hematológicas
EP3661965A4 (en) 2017-08-02 2022-07-13 Phanes Therapeutics, Inc. ANTI-CD47 ANTIBODIES AND USES THEREOF
JP7308191B2 (ja) 2017-10-18 2023-07-13 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７剤ベースの卵巣癌療法
EP4194470A1 (en) 2017-10-18 2023-06-14 Forty Seven, Inc. Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
MX2020005463A (es) 2017-12-01 2020-09-07 Seattle Genetics Inc Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
AU2019218271B2 (en) * 2018-02-12 2024-12-12 Forty Seven, LLC Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies
CA3094098A1 (en) 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
PE20211491A1 (es) 2018-09-27 2021-08-11 Celgene Corp PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS
WO2020163692A1 (en) * 2019-02-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway
JP2022533253A (ja) * 2019-05-24 2022-07-21 フォーティ セブン， インコーポレイテッド ｃ－ｋｉｔ及びＣＤ４７に対する免疫療法剤の同時投与レジメン
KR20220044904A (ko) 2019-05-31 2022-04-12 알렉소 온콜로지 인크. 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법
JP7561775B2 (ja) * 2019-06-07 2024-10-04 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬
PH12022550835A1 (en) * 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
BR112022008817A2 (pt) 2019-11-27 2022-07-26 Alx Oncology Inc Terapias combinadas para tratamento de câncer
AU2020410410A1 (en) 2019-12-17 2022-06-09 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
IL301972A (en) * 2020-10-09 2023-06-01 Sana Biotechnology Inc Methods for activating safe killing mechanisms using the CD47–SIRPα blocking factor
EP4262828A1 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
US12098214B2 (en) 2021-05-13 2024-09-24 ALX Oncology Inc. Combination therapies for treating cancer
EP4376856A1 (en) * 2021-07-28 2024-06-05 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2023092089A1 (en) 2021-11-19 2023-05-25 Kist (Korea Institute Of Science And Technology) Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell
US20230287132A1 (en) * 2022-01-10 2023-09-14 Kiniksa Pharmaceuticals, Ltd. Methods of treating or reducing risk of transplant rejection
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
CN120202222A (zh) 2022-11-16 2025-06-24 勃林格殷格翰国际有限公司 抗SIRPa抗体的疗效预测性生物标志物
TW202440151A (zh) 2022-12-09 2024-10-16 美商輝瑞大藥廠 Ｃｄ４７阻斷劑及抗ｃｄ２０／抗ｃｄ３雙特異性抗體組合療法
WO2024121777A1 (en) 2022-12-09 2024-06-13 Pfizer Inc. Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
US7282556B2 (en) * 2001-05-15 2007-10-16 Emory University Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
US20070113297A1 (en) 2005-09-13 2007-05-17 Yongguang Yang Methods and compositions for inhibition of immune responses
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP2573112A1 (en) * 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
CN101456911A (zh) * 2007-12-12 2009-06-17 江苏豪森药业股份有限公司 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
CA2965198C (en) 2008-01-15 2021-02-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
PL2477648T3 (pl) * 2009-09-15 2022-11-07 The Board Of Trustees Of The Leland Stanford Junior University Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych
US9151760B2 (en) * 2009-09-29 2015-10-06 The Board Of Trustees Of The Leland Stanford Junior University Isolation and use of melanoma cancer stem cells
HUE060541T2 (hu) 2010-05-14 2023-03-28 Univ Leland Stanford Junior Humanizált és kiméra monoklonális CD47 elleni ellenanyagok
RS60606B1 (sr) 2012-01-17 2020-08-31 Univ Leland Stanford Junior Reagensi sirp-alfa visokog affiniteta
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
RS59159B1 (sr) * 2012-02-06 2019-10-31 Inhibrx Inc Cd47 antitela i postupci za njihovu upotrebu
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
PE20151408A1 (es) * 2013-02-06 2015-10-15 Inhibrx Llc Anticuerpos cd47 que no agotan plaquetas ni globulos rojos y metodos de uso de los mismos
EP2970493B1 (en) * 2013-03-15 2019-04-03 The Board of Trustees of the Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents

Also Published As

Publication number Publication date
EP2970493B1 (en) 2019-04-03
CN105189556A (zh) 2015-12-23
CN112245586A (zh) 2021-01-22
US20170145096A1 (en) 2017-05-25
IL241347B (en) 2020-03-31
US10301387B2 (en) 2019-05-28
US20210380689A1 (en) 2021-12-09
AU2020270485B2 (en) 2024-05-23
EP2970493A4 (en) 2016-11-02
JP2023075275A (ja) 2023-05-30
JP6704974B2 (ja) 2020-06-03
US12258403B2 (en) 2025-03-25
US12258399B2 (en) 2025-03-25
JP2020128414A (ja) 2020-08-27
EP3536709A1 (en) 2019-09-11
AU2019200294B2 (en) 2020-08-20
US9623079B2 (en) 2017-04-18
US11518806B2 (en) 2022-12-06
AU2020270485A1 (en) 2020-12-17
US11104731B2 (en) 2021-08-31
US20220251199A1 (en) 2022-08-11
HK1219956A1 (en) 2017-04-21
US20190218289A1 (en) 2019-07-18
JP7562736B2 (ja) 2024-10-07
WO2014149477A8 (en) 2014-11-06
DK2970493T3 (da) 2019-05-13
US11136391B2 (en) 2021-10-05
AU2019200294A1 (en) 2019-02-07
EP3792285A1 (en) 2021-03-17
US20160008429A1 (en) 2016-01-14
JP2019031545A (ja) 2019-02-28
US11603404B2 (en) 2023-03-14
WO2014149477A1 (en) 2014-09-25
JP7246528B2 (ja) 2023-03-27
PT2970493T (pt) 2019-06-27
EP2970493A1 (en) 2016-01-20
AU2014238105B2 (en) 2018-11-15
AU2014238105A1 (en) 2015-08-27
JP7007422B2 (ja) 2022-01-24
JP2022050544A (ja) 2022-03-30
JP2016513640A (ja) 2016-05-16
US20230303688A1 (en) 2023-09-28
CN114917336A (zh) 2022-08-19
IL241347A0 (en) 2015-11-30
CA2903773A1 (en) 2014-09-25
AU2024210996A1 (en) 2024-09-05
US20210079093A1 (en) 2021-03-18
US20220289845A1 (en) 2022-09-15
ES2728066T3 (es) 2019-10-22

Similar Documents

Publication Publication Date Title
JP7246528B2 (ja) 抗ｃｄ４７薬の処理上有効量を達成するための方法
KR20180134367A (ko) 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
HK40042379A (en) Methods for achieving therapeutically effective doses of anti-cd47 agents
HK40074499A (en) Methods for achieving therapeutically effective doses of anti-cd47 agents
HK40035245A (en) Methods for achieving therapeutically effective doses of anti-cd47 agents
HK1219956B (en) Methods for achieving therapeutically effective doses of anti-cd47 agents
HK40108467A (zh) 用於确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181025

R150 Certificate of patent or registration of utility model

Ref document number: 6426693

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250